After finishing at $36.9 in the prior trading day, TG Therapeutics Inc (NASDAQ: TGTX) closed at $35.99, down -2.47%. In other words, the price has decreased by -$2.47 from its previous closing price. On the day, 1.75 million shares were traded. TGTX stock price reached its highest trading level at $37.61 during the session, while it also had its lowest trading level at $35.6352.
Ratios:
Our goal is to gain a better understanding of TGTX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.04 and its Current Ratio is at 4.02. In the meantime, Its Debt-to-Equity ratio is 1.07 whereas as Long-Term Debt/Eq ratio is at 1.06.
On October 29, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $50.
Goldman Upgraded its Sell to Neutral on August 02, 2023, whereas the target price for the stock was revised from $16 to $12.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 13 ’25 when Echelard Yann sold 10,000 shares for $36.94 per share. The transaction valued at 369,400 led to the insider holds 228,816 shares of the business.
Echelard Yann bought 10,000 shares of TGTX for $369,348 on Jun 13 ’25. On Jan 03 ’25, another insider, Power Sean A, who serves as the CFO of the company, sold 11,337 shares for $30.29 each. As a result, the insider received 343,443 and left with 670,632 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TGTX now has a Market Capitalization of 5858056192 and an Enterprise Value of 5226260480. As of this moment, TG’s Price-to-Earnings (P/E) ratio for their current fiscal year is 147.50, and their Forward P/E ratio for the next fiscal year is 20.35. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.97. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.79 while its Price-to-Book (P/B) ratio in mrq is 23.99. Its current Enterprise Value per Revenue stands at 13.526 whereas that against EBITDA is 87.296.
Stock Price History:
The Beta on a monthly basis for TGTX is 1.95, which has changed by 0.8735033 over the last 52 weeks, in comparison to a change of 0.17535925 over the same period for the S&P500. Over the past 52 weeks, TGTX has reached a high of $46.48, while it has fallen to a 52-week low of $16.65. The 50-Day Moving Average of the stock is -1.83%, while the 200-Day Moving Average is calculated to be 6.48%.
Shares Statistics:
The stock has traded on average 2.08M shares per day over the past 3-months and 1556070 shares per day over the last 10 days, according to various share statistics. A total of 158.17M shares are outstanding, with a floating share count of 142.98M. Insiders hold about 9.93% of the company’s shares, while institutions hold 62.39% stake in the company. Shares short for TGTX as of 1752537600 were 24169314 with a Short Ratio of 11.61, compared to 1749772800 on 23697171. Therefore, it implies a Short% of Shares Outstanding of 24169314 and a Short% of Float of 19.91.
